Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Safety and efficacy of daratumumab, carfilzomib, pomalidomide & elotuzumab in POEMS syndrome

Iuliana Vaxman • 12 Jun 2022
EHA 2022
POEMS Syndrome Rare Diseases Antibodies Carfilzomib Daratumumab Elotuzumab Pomalidomide Thalidomide

Iuliana Vaxman, MD, Mayo Clinic, Rochester, MN, discusses the results of a study evaluating the safety and efficacy of daratumumab, carfilzomib, pomalidomide, and elotuzumab in patients with POEMS syndrome treated at Mayo Clinic. The study found that patients treated with these agents achieved deep responses, and there were no treatment-related deaths. In the future, it is important to assess these drugs in randomized clinical trials and determine optimal treatment sequencing strategies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Iuliana Vaxman

2:11
Selecting patients with AL amyloidosis for autoHSCT
Iuliana Vaxman • 12 Jun 2022
1:38
The safety and efficacy of belantamab mafodotin in R/R multiple myeloma in the real world
Iuliana Vaxman • 12 Jun 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals